Brief: TScan Therapeutics Q3 Net Income USD -35.71 Million
12/11/2025 12:00
Nov 12 (Reuters) - TScan Therapeutics Q3 operating expenses USD 39.563 million. Q3 basic EPS USD -0.28 Q3 collaboration and license revenue USD 2.511 million Q3 income from operations USD -37.052 million
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing